• Eikon Therapeutics named Ching-Pin “CP” Chang executive vice president, chief scientific officer.
• Chang joins from Bristol Myers Squibb, most recently vice president, head of cardiovascular discovery biology and translational pharmacology.
• Earlier roles included head of cardiovascular research at Gilead Sciences, vice president of disease biology at MyoKardia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eikon Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609030730PRIMZONEFULLFEED9820765) on September 03, 2026, and is solely responsible for the information contained therein.